aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment, achieved in the fourth quarter of the financial year 2007 - according to preliminary figures - a quarterly sales record of EUR 9.5 million (+121% to fourth quarter 2006). Sales of total financial year 2007 were up to a new level of EUR 28.1 million, a year-to-year increase of 52%.
In 2007, the group companies active in the field of medical biomaterials ("aap bio implants group"), achieved sales of EUR 20.1 million (previous year: EUR 12.2 million, + 65%). This significant increase results to a large extent from the acquisition and initial consolidation of the Dutch Fame Medical Group.
The Berlin based trauma & orthopaedics division of the company reached for the full financial year 2007 a strong organic sales increase of 29% to EUR 8.0 million (previous year: EUR 6.2 million).
For 2008 aap anticipates an organic sales growth of more than 20%, with above-average impact of the company´s operating result and net income. The publication of the full annual financial statements 2007 is planned for March 28, 2008.
In 2007, the group companies active in the field of medical biomaterials ("aap bio implants group"), achieved sales of EUR 20.1 million (previous year: EUR 12.2 million, + 65%). This significant increase results to a large extent from the acquisition and initial consolidation of the Dutch Fame Medical Group.
The Berlin based trauma & orthopaedics division of the company reached for the full financial year 2007 a strong organic sales increase of 29% to EUR 8.0 million (previous year: EUR 6.2 million).
For 2008 aap anticipates an organic sales growth of more than 20%, with above-average impact of the company´s operating result and net income. The publication of the full annual financial statements 2007 is planned for March 28, 2008.
